Improving Clinical Decision Making with Engaging CME, Tools, & Resources
Trends in PDR Treatments
Maria H. Berrocal, MD
Katharine Talcott, MD
GLP-1 Use and AMD Risk
Barton Lynn Blackorby, MD
Hong-Uyen Hua, MD
MH Risk Factors After RRD Repair
Avni P. Finn, MD, MBA
Signaling for Sustained Change: Spotlight on the Potential of TKIs to Deliver Durable Control of Exudative Retinal Disease
Katherine E. Talcott, MD
Christina Y. Weng, MD, MBA, FASRS
Roger A. Goldberg, MD, MBA
Identifying Central and Branch Retinal Vein Occlusion
Jessica Randolph, MD
Outcomes for PDR Patients LTFU for at Least 1 Year
Kyle Davis Kovacs, MD
Matt Starr, MD
Nita Valikodath, MD, MS
Real-World Switching to Faricimab from Legacy Anti-VEGFs in Wet AMD
Lejla Vajzovic, MD, FASRS
How Anti-VEGF Compares with Steroids in Retinal Vein Occlusion
Ryan Quigley
Racial/Ethnic Disparities in TDR, DME, and Other Vision Threats in Patients With DR
Jordan Deaner
Vaidehi S. Dedania, MD
Rehan M. Hussain, MD
Logistical Considerations with Anti-VEGF Treatment in Wet AMD
Examining Therapeutic Timing in RVO-Related Macular Edema
Suprachoroidal Steroids in Patients With a History of Glaucoma and Ocular Hypertension
Danny Mammo, MD
Diagnosis Delays in Stargardt Disease
Alexis Warren, MD
Jesse Sengillo, MD
Sruthi Arepalli, MD
Practice Efficiency and Innovation
Jacob Lang
Redefining The Cash-Pay Model in Modern Optometric Practice
Jason E. Compton, OD, FAAO
Tailored Treatment in Retinal Disease: Using Biomarkers to Guide Anti-VEGF Therapy
Jennifer Caudle, DO, FACOFP
Michael Javaheri, MD, MSc, FASRS
Loading...
We're glad to see you're enjoying Eye Health Academy… but how about a more personalized experience?
Press cancel to remain on Eye Health Academy. Press the link below or the continue button to keep going.